XML 45 R39.htm IDEA: XBRL DOCUMENT
v3.25.1

Reportable Segment Information (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Summary of Financial Information for Each Reportable Segment | The following table presents various financial information for each reportable segment:
| Three months ended |  |  | Six months ended |
| March 31 |  |  | March 31 |
(In millions - unaudited) | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
SALES |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 172 |  |  | $ | 222 |  |  | $ | 306 |  |  | $ | 422 |
Personal Care |  | 146 |  |  |  | 169 |  |  |  | 279 |  |  |  | 298 |
Specialty Additives |  | 134 |  |  |  | 157 |  |  |  | 249 |  |  |  | 279 |
Intermediates |  | 37 |  |  |  | 40 |  |  |  | 71 |  |  |  | 73 |
Intersegment sales(a) |  | (10 | ) |  |  | (13 | ) |  |  | (21 | ) |  |  | (24 | )
| $ | 479 |  |  | $ | 575 |  |  | $ | 884 |  |  | $ | 1,048 |
OPERATING INCOME (LOSS) |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 28 |  |  | $ | 50 |  |  | $ | 42 |  |  | $ | 82 |
Personal Care |  | 28 |  |  |  | 25 |  |  |  | 39 |  |  |  | 28 |
Specialty Additives |  | 7 |  |  |  | (18 | ) |  |  | 2 |  |  |  | (50 | )
Intermediates |  | (1 | ) |  |  | 9 |  |  |  | 2 |  |  |  | 16 |
Unallocated and other(b) |  | (11 | ) |  |  | (45 | ) |  |  | (213 | ) |  |  | (72 | )
| $ | 51 |  |  | $ | 21 |  |  | $ | (128 | ) |  | $ | 4 |
DEPRECIATION EXPENSE |  |  |  |  |  |  |  |  |  |  |
Life Sciences(c) | $ | 22 |  |  | $ | 11 |  |  | $ | 31 |  |  | $ | 20 |
Personal Care |  | 7 |  |  |  | 9 |  |  |  | 15 |  |  |  | 17 |
Specialty Additives(d) |  | 13 |  |  |  | 40 |  |  |  | 27 |  |  |  | 77 |
Intermediates |  | 3 |  |  |  | 3 |  |  |  | 6 |  |  |  | 6 |
| $ | 45 |  |  | $ | 63 |  |  | $ | 79 |  |  | $ | 120 |
AMORTIZATION EXPENSE |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 4 |  |  | $ | 5 |  |  | $ | 8 |  |  | $ | 12 |
Personal Care |  | 8 |  |  |  | 11 |  |  |  | 19 |  |  |  | 22 |
Specialty Additives |  | 3 |  |  |  | 4 |  |  |  | 5 |  |  |  | 6 |
Intermediates |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
| $ | 15 |  |  | $ | 20 |  |  | $ | 32 |  |  | $ | 40 |
EBITDA(e) |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 54 |  |  | $ | 66 |  |  | $ | 81 |  |  | $ | 114 |
Personal Care |  | 43 |  |  |  | 45 |  |  |  | 73 |  |  |  | 67 |
Specialty Additives |  | 23 |  |  |  | 26 |  |  |  | 34 |  |  |  | 33 |
Intermediates |  | 2 |  |  |  | 12 |  |  |  | 8 |  |  |  | 22 |
Unallocated and other |  | (11 | ) |  |  | (45 | ) |  |  | (213 | ) |  |  | (72 | )
| $ | 111 |  |  | $ | 104 |  |  | $ | (17 | ) |  | $ | 164 |
| March 31 |  |  | September 30 |
(In millions - unaudited) | 2025 |  |  | 2024 |
TOTAL ASSETS |  |  |  |  |
Life Sciences | $ | 1,876 |  |  | $ | 1,778 |
Personal Care |  | 702 |  |  |  | 950 |
Specialty Additives |  | 1,355 |  |  |  | 1,516 |
Intermediates |  | 119 |  |  |  | 127 |
Unallocated and other |  | 1,181 |  |  |  | 1,274 |
| $ | 5,233 |  |  | $ | 5,645 |
(a) Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost. (b) Includes a $8 million gain on sale for the three and six months ended March 31, 2025 and a $183 million impairment charge for the six months ended March 31, 2025, both related to the sale of the Avoca business within income (loss) on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss). (c) Depreciation includes accelerated depreciation of $13 million for Life Sciences for the three and six months ended March 31, 2025. (d) Depreciation includes accelerated depreciation of $27 million and $49 million for Specialty Additives for the three and six months ended March 31, 2024, respectively. (e) Excludes income (loss) from discontinued operations and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration